Home Sectors Healthcare Present Change: Globus Medical (NYSE: GMED)

Present Change: Globus Medical (NYSE: GMED)


Globus Medical is in the medical devices industry and is in the healthcare sector. The company CEO is David M. Demski. Globus Medical Inc is a medical device company. It operates under two divisions that include innovative fusion and disruptive technology developing products for patients with musculoskeletal disorders for various treatment.

Previous Intraday Trading Performance:

The GMED stock showed a previous change of 1.90% with an open at 39.97 and a close of 40.33. It reached an intraday high of 40.67 and a low of 39.82.

SeekingAlpha:  RBC cuts rating on BioCryst on disappointing BCX7353 data; down 4% premarket


The stock has a market cap of $4.0b with 99.0m shares outstanding, of which the float is 98.0m shares. Trading volume reached 407,406 shares compared to its average volume of 658,440 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Globus Medical shares returned 1.72% and in the past 30 trading days it returned -10.95%. Over three months, it changed -14.77%. In one year it has changed -28.17% and within that year its 52-week high was 57.83 and its 52-week low was 38.01. GMED stock is 6.10% above its 52 Week Low.

Our calculations show a 200 day moving average of 47.74 and a 50 day moving average of 44.61. Currently GMED stock is trading -15.53% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  RBC cuts rating on BioCryst on disappointing BCX7353 data; down 4% premarket


The last annual fiscal EPS for the company was reported at 1.54 that ended on 31st of December 2018, which according to the previous close, that is a PE of 26.19. Based on 6 analyst estimates, the consensus EPS for the next quarter is 0.41. The TTM EPS is 1.67, which comes to a TTM PE of 24.15. Historically, the PE high was 52.60 and the PE low was 16.30. If the stock reached its PE low, that would represent a price of 27.22, which is a decrease of -32.51%.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 (Reported on 05/02/2019): 0.33
4thQtr of 2018 (Reported on 02/21/2019): 0.36
3rdQtr of 2018 (Reported on 11/08/2018): 0.35
2ndQtr of 2018 (Reported on 08/01/2018): 0.44
1stQtr of 2018 (Reported on 05/02/2018): 0.39

Base on our calculations, the intrinsic value per share is 28.78, which means it may be overvalued by -40.13%.

Indicators to Watch:

Short-interest was 2,675,008, which was 2.70% of shares outstanding. The short-interest ratio or days-to-cover ratio was 5.20. This stock has some short interest, but it may be normal and no cause for concern if long the position.

The current calculated beta is 0.90.

SeekingAlpha:  Sector Study: Consumer Cyclical Vs. Consumer Defensive Dividend Dogs, Which To Buy?

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 13.82%, return on assets is 12.71%, profit margin is 20.96%, price-to-sales is 5.43 and price-to-book is 3.17.

Company Scores:

All scores are out of six:
 2  :Valuation Score
 3  :Past Performance Score
 5  :Financial Strength Score
 3  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.